Bristol-Myers NASH drug reduces liver fat in midstage study

April 22 (Reuters) - Bristol-Myers Squibb Co said

its lead experimental drug for nonalcoholic steatohepatitis, or

NASH, significantly reduced liver fat versus placebo, according

to data from a mid-stage trial presented at a medical meeting on

Saturday.

Read more